✦ LIBER ✦

Phase I Trial of a B7-1 (CD80) Gene Modified Autologous Tumor Cell Vaccine in Combination With Systemic Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma

✍ Scribed by ANTONIA, SCOTT J.; SEIGNE, JOHN; DIAZ, JOSE; MURO-CACHO, CARLOS; EXTERMANN, MARTINE; FARMELO, MARY JANE; FRIBERG, MARIA; ALSARRAJ, MARWAN; MAHANY, J.J.; POW-SANG, JULIO; CANTOR, ALAN; JANSSEN, WILLIAM

Book ID: 123074297
Publisher: Lippincott Williams and Wilkins
Year: 2002
Tongue: English
Weight: 635 KB
Volume: 167
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(05)65071-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

970 ALLOGENEIC GENETICALLY-MODIFIED TUMO

970 ALLOGENEIC GENETICALLY-MODIFIED TUMOR CELL VACCINE (RCC-26/CD80/IL-2) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA - A PHASE I TRIAL

✍ A. Buchner; H. Pohla; A. Baur; J. Kopp; A. Pezzutto; T. Blankenstein; D. Schende 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 316 KB

Allogeneic gene-modified tumor cells (RC

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study

✍ Westermann, J; Flörcken, A; Willimsky, G; van Lessen, A; Kopp, J; Takvorian, A; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 715 KB

Quality of life in patients with metasta

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine

✍ Lorenzo Cohen; Carl de Moor; Patricia A Parker; Robert J Amato 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 113 KB

IMMUNE MONITORING OF AN ALLOGENIC GENETI

IMMUNE MONITORING OF AN ALLOGENIC GENETICALLY- MODIFIED TUMOR CELL VACCINE (RCC-26/CD80/IL-2) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

✍ Buchner, Alexander; Pohla, Heike; Frankenberger, Bernhard; Baur, Andrea; Stief, 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 124 KB

Phase I/II study of thalidomide in combi

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

✍ Robert J. Amato; Margaret Morgan; Anish Rawat 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

A phase I/II trial with chimeric monoclo

A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low dose interleukin-2 for patients with metastatic renal cell carcinoma

✍ I. Bleumer; J. Beck; Oosterwijk; C. Mala; S. Ullrich; P.F.A. Mulders 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 199 KB